CEL-SCI Corporation  

(Public, NYSEAMERICAN:CVM)   Watch this stock  
Find more results for AMEX:CVM
+0.06 (3.26%)
Mar 16 - Close
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 1.83 - 1.90
52 week 1.46 - 3.92
Open 1.83
Vol / Avg. 67,553.00/102,149.00
Mkt cap 26.59M
P/E     -
Div/yield     -
EPS -2.73
Shares 13.99M
Beta -1.29
Inst. own 10%

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -5432.69% -20810.33%
Operating margin -4312.05% -30916.13%
EBITD margin - -29999.00%
Return on average assets -110.07% -60.08%
Return on average equity - -
Employees 43 -
CDP Score - -


8229 Boone Blvd Ste 802
VIENNA, VA 22182-2634
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Officers and directors

Geert R. Kersten Esq. Chief Executive Officer, Treasurer, Director
Age: 56
Bio & Compensation  - Reuters
Patricia B Prichep Senior Vice President - Operations, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
John Cipriano Senior Vice President - Regulatory Affairs
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel H Zimmerman Ph.D. Senior Vice President - Research, Cellular Immunology
Age: 73
Bio & Compensation  - Reuters
Eyal Talor Ph.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Robert E. Watson Director
Age: 59
Bio & Compensation  - Reuters
Alexander G. Esterhazy Independent Director
Age: 73
Bio & Compensation  - Reuters
Peter R. Young Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters